Integrated analysis of plasma and urine reveals unique metabolomic profiles in idiopathic inflammatory myopathies subtypes

Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis‐specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and progno...

Full description

Saved in:
Bibliographic Details
Published inJournal of cachexia, sarcopenia and muscle Vol. 13; no. 5; pp. 2456 - 2472
Main Authors Liu, Di, Zhao, Lijuan, Jiang, Yu, Li, Liya, Guo, Muyao, Mu, Yibing, Zhu, Honglin
Format Journal Article
LanguageEnglish
Published Germany John Wiley & Sons, Inc 01.10.2022
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text
ISSN2190-5991
2190-6009
2190-6009
DOI10.1002/jcsm.13045

Cover

Abstract Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis‐specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed. Methods Plasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high‐performance liquid chromatography of quadrupole time‐of‐flight mass spectrometry (HPLC‐Q‐TOF‐MS)/MS‐based untargeted metabolomics. Orthogonal partial least‐squares discriminate analysis (OPLS‐DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers. Results OPLS‐DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti‐synthetase syndrome (ASS), and immune‐mediated necrotizing myopathy (IMNM)] and MSA‐defined subtypes (anti‐Mi2+, anti‐MDA5+, anti‐TIF1γ+, anti‐Jo1+, anti‐PL7+, anti‐PL12+, anti‐EJ+, and anti‐SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA‐defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti‐EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = −0.416, P = 0.005) and urine malonyl carnitine (r = −0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease. Conclusions In both plasma and urine samples, IIM main and MSA‐defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
AbstractList Abstract Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis‐specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed. Methods Plasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high‐performance liquid chromatography of quadrupole time‐of‐flight mass spectrometry (HPLC‐Q‐TOF‐MS)/MS‐based untargeted metabolomics. Orthogonal partial least‐squares discriminate analysis (OPLS‐DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers. Results OPLS‐DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti‐synthetase syndrome (ASS), and immune‐mediated necrotizing myopathy (IMNM)] and MSA‐defined subtypes (anti‐Mi2+, anti‐MDA5+, anti‐TIF1γ+, anti‐Jo1+, anti‐PL7+, anti‐PL12+, anti‐EJ+, and anti‐SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA‐defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti‐EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = −0.416, P = 0.005) and urine malonyl carnitine (r = −0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease. Conclusions In both plasma and urine samples, IIM main and MSA‐defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis-specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed. Plasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high-performance liquid chromatography of quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)/MS-based untargeted metabolomics. Orthogonal partial least-squares discriminate analysis (OPLS-DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers. OPLS-DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti-synthetase syndrome (ASS), and immune-mediated necrotizing myopathy (IMNM)] and MSA-defined subtypes (anti-Mi2+, anti-MDA5+, anti-TIF1γ+, anti-Jo1+, anti-PL7+, anti-PL12+, anti-EJ+, and anti-SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA-defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti-EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = -0.416, P = 0.005) and urine malonyl carnitine (r = -0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease. In both plasma and urine samples, IIM main and MSA-defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis-specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed.OBJECTIVESIdiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis-specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed.Plasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high-performance liquid chromatography of quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)/MS-based untargeted metabolomics. Orthogonal partial least-squares discriminate analysis (OPLS-DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers.METHODSPlasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high-performance liquid chromatography of quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)/MS-based untargeted metabolomics. Orthogonal partial least-squares discriminate analysis (OPLS-DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers.OPLS-DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti-synthetase syndrome (ASS), and immune-mediated necrotizing myopathy (IMNM)] and MSA-defined subtypes (anti-Mi2+, anti-MDA5+, anti-TIF1γ+, anti-Jo1+, anti-PL7+, anti-PL12+, anti-EJ+, and anti-SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA-defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti-EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = -0.416, P = 0.005) and urine malonyl carnitine (r = -0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease.RESULTSOPLS-DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti-synthetase syndrome (ASS), and immune-mediated necrotizing myopathy (IMNM)] and MSA-defined subtypes (anti-Mi2+, anti-MDA5+, anti-TIF1γ+, anti-Jo1+, anti-PL7+, anti-PL12+, anti-EJ+, and anti-SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA-defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti-EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = -0.416, P = 0.005) and urine malonyl carnitine (r = -0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease.In both plasma and urine samples, IIM main and MSA-defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.CONCLUSIONSIn both plasma and urine samples, IIM main and MSA-defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
ObjectivesIdiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis‐specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed.MethodsPlasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high‐performance liquid chromatography of quadrupole time‐of‐flight mass spectrometry (HPLC‐Q‐TOF‐MS)/MS‐based untargeted metabolomics. Orthogonal partial least‐squares discriminate analysis (OPLS‐DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers.ResultsOPLS‐DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti‐synthetase syndrome (ASS), and immune‐mediated necrotizing myopathy (IMNM)] and MSA‐defined subtypes (anti‐Mi2+, anti‐MDA5+, anti‐TIF1γ+, anti‐Jo1+, anti‐PL7+, anti‐PL12+, anti‐EJ+, and anti‐SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA‐defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti‐EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = −0.416, P = 0.005) and urine malonyl carnitine (r = −0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease.ConclusionsIn both plasma and urine samples, IIM main and MSA‐defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on clinical manifestations and myositis‐specific autoantibodies (MSAs). However, even in each IIM subtype, the clinical symptoms and prognoses of patients are very different. Thus, the identification of more potential biomarkers associated with IIM classification, clinical symptoms, and prognosis is urgently needed. Methods Plasma and urine samples from 79 newly diagnosed IIM patients (mean disease duration 4 months) and 52 normal control (NC) samples were analysed by high‐performance liquid chromatography of quadrupole time‐of‐flight mass spectrometry (HPLC‐Q‐TOF‐MS)/MS‐based untargeted metabolomics. Orthogonal partial least‐squares discriminate analysis (OPLS‐DA) were performed to measure the significance of metabolites. Pathway enrichment analysis was conducted based on the KEGG human metabolic pathways. Ten machine learning (ML) algorithms [linear support vector machine (SVM), radial basis function SVM, random forest, nearest neighbour, Gaussian processes, decision trees, neural networks, adaptive boosting (AdaBoost), Gaussian naive Bayes and quadratic discriminant analysis] were used to classify each IIM subtype and select the most important metabolites as potential biomarkers. Results OPLS‐DA showed a clear separation between NC and IIM subtypes in plasma and urine metabolic profiles. KEGG pathway enrichment analysis revealed multiple unique and shared disturbed metabolic pathways in IIM main [dermatomyositis (DM), anti‐synthetase syndrome (ASS), and immune‐mediated necrotizing myopathy (IMNM)] and MSA‐defined subtypes (anti‐Mi2+, anti‐MDA5+, anti‐TIF1γ+, anti‐Jo1+, anti‐PL7+, anti‐PL12+, anti‐EJ+, and anti‐SRP+), such that fatty acid biosynthesis was significantly altered in both plasma and urine in all main IIM subtypes (enrichment ratio > 1). Random forest and AdaBoost performed best in classifying each IIM subtype among the 10 ML models. Using the feature selection methods in ML models, we identified 9 plasma and 10 urine metabolites that contributed most to separate IIM main subtypes and MSA‐defined subtypes, such as plasma creatine (fold change = 3.344, P = 0.024) in IMNM subtype and urine tiglylcarnitine (fold change = 0.351, P = 0.037) in anti‐EJ+ ASS subtype. Sixteen common metabolites were found in both the plasma and urine samples of IIM subtypes. Among them, some were correlated with clinical features, such as plasma hypogeic acid (r = −0.416, P = 0.005) and urine malonyl carnitine (r = −0.374, P = 0.042), which were negatively correlated with the prevalence of interstitial lung disease. Conclusions In both plasma and urine samples, IIM main and MSA‐defined subtypes have specific metabolic signatures and pathways. This study provides useful clues for understanding the molecular mechanisms, searching potential diagnosis biomarkers and therapeutic targets for IIM.
Author Mu, Yibing
Guo, Muyao
Zhao, Lijuan
Li, Liya
Zhu, Honglin
Liu, Di
Jiang, Yu
AuthorAffiliation 5 Department of Rheumatology and Immunology, The Third Xiangya Hospital Central South University Changsha Hunan China
3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University Changsha Hunan China
2 Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China
4 Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Institute of Emergency Medicine Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University Changsha Hunan China
6 Department of Nutrition Hunan Provincial Maternal and Child Health Care Hospital Changsha Hunan China
1 Department of Rheumatology and Immunology, Xiangya Hospital Central South University Changsha Hunan China
AuthorAffiliation_xml – name: 1 Department of Rheumatology and Immunology, Xiangya Hospital Central South University Changsha Hunan China
– name: 5 Department of Rheumatology and Immunology, The Third Xiangya Hospital Central South University Changsha Hunan China
– name: 2 Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China
– name: 6 Department of Nutrition Hunan Provincial Maternal and Child Health Care Hospital Changsha Hunan China
– name: 3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University Changsha Hunan China
– name: 4 Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Institute of Emergency Medicine Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University Changsha Hunan China
Author_xml – sequence: 1
  givenname: Di
  surname: Liu
  fullname: Liu, Di
  organization: Sun Yat‐sen University
– sequence: 2
  givenname: Lijuan
  surname: Zhao
  fullname: Zhao, Lijuan
  organization: Central South University
– sequence: 3
  givenname: Yu
  surname: Jiang
  fullname: Jiang, Yu
  organization: Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University
– sequence: 4
  givenname: Liya
  surname: Li
  fullname: Li, Liya
  organization: Central South University
– sequence: 5
  givenname: Muyao
  surname: Guo
  fullname: Guo, Muyao
  organization: Central South University
– sequence: 6
  givenname: Yibing
  surname: Mu
  fullname: Mu, Yibing
  organization: Hunan Provincial Maternal and Child Health Care Hospital
– sequence: 7
  givenname: Honglin
  surname: Zhu
  fullname: Zhu, Honglin
  email: honglinzhu@csu.edu.cn
  organization: Central South University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35860906$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNUREvphgdAkdgg0JTjXOzxBgmNuBQVsaB768Q5aT1y7GAnrcLT45mUilao3tj6_Z1f5_Y8O3DeUZa9ZHDKAIr3Wx37U1ZCVT_JjgomYcUB5MHtu5aSHWYnMW4hnYozXsOz7LCs1xwk8KPs95kb6TLgSG2ODu0cTcx9lw8WY49JavMpGEd5oGtCG_PJmV8T5T2N2Hjre6PzIfjOWIq5cblpjR9wvEqycZ3FvsfRhznv50VOVJyacR4ovsiedsmRTm7v4-zi86eLzdfV-Y8vZ5uP5ytds6peCayo1Z0g0ULRYkdrFNAQaKElQ14Q08CZWOuSsZbEmiMjbDQn7GRTlOVxdrbYth63agimxzArj0btBR8uFYbRaEsKa8FKQgTNdFWhlFBgpYXsqqZtOPLk9W7xmtyA8w1ae2fIQO3moXbzUPt5JPrDQg9T06cayI0B7b0U7v84c6Uu_bWSdQl1JZPBm1uD4FPT46h6EzVZi478FFXBZSHqmkOV0NcP0K2fQhpookQBogKxp179m9FdKn_3IQGwADr4GAN1SpsRR-N3CRr7_yrfPgh5tCVsgW_SwsyPkOrb5uf3JeYP1sPrMQ
CitedBy_id crossref_primary_10_1016_j_metabol_2023_155587
crossref_primary_10_1021_acsomega_4c03111
crossref_primary_10_3390_ijms232415805
crossref_primary_10_1016_j_envpol_2024_125094
crossref_primary_10_1002_cti2_1504
crossref_primary_10_1021_acs_analchem_2c05558
crossref_primary_10_1021_acs_analchem_3c03212
crossref_primary_10_1007_s10278_024_01168_w
crossref_primary_10_3389_fnins_2022_1002590
crossref_primary_10_1109_ACCESS_2023_3320798
crossref_primary_10_1093_bib_bbad514
crossref_primary_10_1016_j_trsl_2023_08_001
crossref_primary_10_3389_fimmu_2023_1169057
Cites_doi 10.1038/nrrheum.2014.2
10.3390/biomedicines8110480
10.1002/mas.21455
10.1016/j.bbrc.2020.02.099
10.1042/BJ20130153
10.1016/j.ymben.2020.06.010
10.1159/000364816
10.1016/j.arr.2018.09.004
10.3389/fendo.2019.00870
10.1111/j.1468-3083.2011.04437.x
10.1002/art.40406
10.1016/j.bbalip.2019.04.003
10.1152/physrev.00035.2018
10.1016/j.biopsych.2010.12.006
10.1038/sj.bjc.6603164
10.1016/j.jacc.2016.06.044
10.1007/s11596-014-1271-7
10.1016/j.cmet.2021.03.025
10.1038/nrrheum.2018.48
10.1093/jnci/djab129
10.1016/j.jnutbio.2005.01.010
10.1007/s11010-016-2688-z
10.1016/j.fct.2020.111594
10.1186/s13075-018-1579-y
10.1093/rheumatology/keaa473
10.1002/art.41733
10.1111/iep.12348
10.1016/j.semarthrit.2020.05.008
10.1021/ac051495j
10.1002/acr.21879
10.1016/j.metabol.2020.154320
10.1016/S1474-4422(18)30254-0
10.1177/1759720X211060907
10.1136/ard.2007.079525
10.1038/s41467‐019‐11129‐5
10.1210/er.2008-0007
10.1016/0009-8981(83)90186-9
10.1016/j.ymgme.2020.07.010
10.1007/s00125-017-4366-4
10.1093/rheumatology/keg084
10.5606/ArchRheumatol.2016.5696
10.3389/fneur.2019.00438
ContentType Journal Article
Copyright 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
– notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1002/jcsm.13045
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Plasma and urine metabolomic profiles in IIM
EISSN 2190-6009
EndPage 2472
ExternalDocumentID oai_doaj_org_article_a5713eaa0c1c44a9902a4c79f4bdb6a6
10.1002/jcsm.13045
PMC9530549
35860906
10_1002_jcsm_13045
JCSM13045
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 82101880
– fundername: Natural Science Foundation of Hunan Province
  funderid: 2020JJ8056
– fundername: National Natural Science Foundation of China
  grantid: 82101880
– fundername: Natural Science Foundation of Hunan Province
  grantid: 2020JJ8056
– fundername: ;
  grantid: 2020JJ8056
– fundername: ;
  grantid: 82101880
GroupedDBID ---
0R~
1OC
24P
2VQ
4.4
40G
53G
5VS
7X7
8FI
8FJ
AAHHS
AAKDD
AAZKR
ABUWG
ACCFJ
ACCMX
ACXQS
ADBBV
ADINQ
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AHBYD
AHSBF
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMKLP
AOIJS
AVUZU
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
DIK
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
ITC
KQ8
M48
M~E
O9-
OK1
OVD
OVEED
PIMPY
PQQKQ
PROAC
RPM
RSV
SMD
SOJ
U2A
UKHRP
WIN
ZOVNA
AAFWJ
AAMMB
AAYXX
AEFGJ
AFPKN
AGXDD
AIDQK
AIDYY
CITATION
PHGZM
PHGZT
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c5145-7a4edcf7e7d02dafe8a70be0c7c91a62e1c06178c311de786a1eabc6eaf9b233
IEDL.DBID M48
ISSN 2190-5991
2190-6009
IngestDate Fri Oct 03 12:35:43 EDT 2025
Sun Oct 26 04:09:50 EDT 2025
Tue Sep 30 17:19:35 EDT 2025
Thu Sep 04 18:20:11 EDT 2025
Tue Oct 07 07:15:22 EDT 2025
Mon Jul 21 05:57:35 EDT 2025
Thu Apr 24 23:06:16 EDT 2025
Wed Oct 01 03:24:47 EDT 2025
Wed Jan 22 16:24:07 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Idiopathic inflammatory myopathies
Biomarkers
Metabolomics
Machine learning algorithm
Language English
License Attribution-NonCommercial-NoDerivs
2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5145-7a4edcf7e7d02dafe8a70be0c7c91a62e1c06178c311de786a1eabc6eaf9b233
Notes Contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/jcsm.13045
PMID 35860906
PQID 2720740704
PQPubID 4370305
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_a5713eaa0c1c44a9902a4c79f4bdb6a6
unpaywall_primary_10_1002_jcsm_13045
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9530549
proquest_miscellaneous_2692755604
proquest_journals_2720740704
pubmed_primary_35860906
crossref_citationtrail_10_1002_jcsm_13045
crossref_primary_10_1002_jcsm_13045
wiley_primary_10_1002_jcsm_13045_JCSM13045
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2022
PublicationDateYYYYMMDD 2022-10-01
PublicationDate_xml – month: 10
  year: 2022
  text: October 2022
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Heidelberg
– name: Hoboken
PublicationTitle Journal of cachexia, sarcopenia and muscle
PublicationTitleAlternate J Cachexia Sarcopenia Muscle
PublicationYear 2022
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2019; 1864
2021; 6
1983; 134
2017; 60
2006; 94
2013; 27
2006; 78
2013; 65
2019; 99
2019; 10
2020; 61
2016; 31
2020; 525
2020; 145
2020; 101
2018; 20
2021; 73
2018; 48
2020; 8
2021; 13
2018; 17
2014; 4
2021; 33
2017; 36
2016; 416
2020; 131
2020; 50
2021; 114
2008; 29
2011; 70
2018; 70
2008; 67
2013; 454
2021; 60
2020; 111S
2005; 16
2003; 42
2014; 34
2016; 68
2018; 14
2014; 10
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
Anupam G (e_1_2_7_11_1) 2021; 6
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
References_xml – volume: 68
  start-page: 1281
  year: 2016
  end-page: 1293
  article-title: Comprehensive metabolomic characterization of coronary artery diseases
  publication-title: J Am Coll Cardiol
– volume: 73
  start-page: 1738
  year: 2021
  end-page: 1748
  article-title: Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout
  publication-title: Arthritis Rheumatol
– volume: 42
  start-page: 298
  year: 2003
  end-page: 303
  article-title: Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis
  publication-title: Rheumatology (Oxford)
– volume: 145
  year: 2020
  article-title: The lysine derivative aminoadipic acid, a biomarker of protein oxidation and diabetes‐risk, induces production of reactive oxygen species and impairs trypsin secretion in mouse pancreatic acinar cells
  publication-title: Food Chem Toxicol
– volume: 33
  start-page: 905
  year: 2021
  end-page: 922
  article-title: The adverse metabolic effects of branched‐chain amino acids are mediated by isoleucine and valine
  publication-title: Cell Metab
– volume: 48
  start-page: 51
  year: 2018
  end-page: 78
  article-title: Significance of urinary 11‐dehydro‐thromboxane B2 in age‐related diseases: Focus on atherothrombosis
  publication-title: Ageing Res Rev
– volume: 10
  start-page: 295
  year: 2014
  end-page: 303
  article-title: The skeletal muscle arachidonic acid cascade in health and inflammatory disease
  publication-title: Nat Rev Rheumatol
– volume: 10
  year: 2019
  article-title: Decreases in circulating concentrations of long‐chain acylcarnitines and free fatty acids during the glucose tolerance test represent tissue‐specific insulin sensitivity
  publication-title: Front Endocrinol (Lausanne)
– volume: 65
  start-page: 793
  year: 2013
  end-page: 799
  article-title: Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease
  publication-title: Arthritis Care Res (Hoboken)
– volume: 99
  start-page: 1819
  year: 2019
  end-page: 1875
  article-title: Metabolomics for investigating physiological and pathophysiological processes
  publication-title: Physiol Rev
– volume: 16
  start-page: 375
  year: 2005
  end-page: 382
  article-title: Moderate intake of myristic acid in sn‐2 position has beneficial lipidic effects and enhances DHA of cholesteryl esters in an interventional study
  publication-title: J Nutr Biochem
– volume: 10
  year: 2019
  article-title: Glycine, serine and threonine metabolism confounds efficacy of complement‐mediated killing
  publication-title: Nat Commun
– volume: 6
  start-page: 515
  year: 2021
  end-page: 526
  article-title: NMR‐based serum and muscle metabolomics for diagnosis and activity assessment in idiopathic inflammatory myopathies
  publication-title: Anal Sci Adv
– volume: 4
  start-page: 252
  year: 2014
  end-page: 262
  article-title: Serum metabolomic biomarkers of dementia
  publication-title: Dement Geriatr Cogn Dis Extra
– volume: 36
  start-page: 115
  year: 2017
  end-page: 134
  article-title: Mass spectrometric based approaches in urine metabolomics and biomarker discovery
  publication-title: Mass Spectrom Rev
– volume: 416
  start-page: 11
  year: 2016
  end-page: 22
  article-title: Mitochondrial defects associated with beta‐alanine toxicity: relevance to hyper‐beta‐alaninemia
  publication-title: Mol Cell Biochem
– volume: 454
  start-page: 91
  year: 2013
  end-page: 99
  article-title: Cell cycle regulation of purine synthesis by phosphoribosyl pyrophosphate and inorganic phosphate
  publication-title: Biochem J
– volume: 134
  start-page: 77
  year: 1983
  end-page: 83
  article-title: Isovalerylglucuronide, a new urinary metabolite in isovaleric acidemia. Identification problems due to rearrangement reactions
  publication-title: Clin Chim Acta
– volume: 17
  start-page: 816
  year: 2018
  end-page: 828
  article-title: Classification and management of adult inflammatory myopathies
  publication-title: Lancet Neurol
– volume: 27
  start-page: 175
  year: 2013
  end-page: 179
  article-title: Lipid profiles in untreated patients with dermatomyositis
  publication-title: J Eur Acad Dermatol Venereol
– volume: 34
  start-page: 276
  year: 2014
  end-page: 283
  article-title: A HPLC‐Q‐TOF‐MS‐based urinary metabolomic approach to identification of potential biomarkers of metabolic syndrome
  publication-title: J Huazhong Univ Sci Technolog Med Sci
– volume: 14
  start-page: 255
  year: 2018
  end-page: 268
  article-title: Risk factors and disease mechanisms in myositis
  publication-title: Nat Rev Rheumatol
– volume: 60
  start-page: 2177
  year: 2021
  end-page: 2189
  article-title: PKM2‐dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis
  publication-title: Rheumatology (Oxford)
– volume: 50
  start-page: 627
  year: 2020
  end-page: 635
  article-title: The altered metabolism profile in pathogenesis of idiopathic inflammatory myopathies
  publication-title: Semin Arthritis Rheum
– volume: 31
  start-page: 133
  year: 2016
  end-page: 138
  article-title: Screening of free carnitine and acylcarnitine status in children with familial Mediterranean fever
  publication-title: Arch Rheumatol
– volume: 78
  start-page: 567
  year: 2006
  end-page: 574
  article-title: Large‐scale human metabolomics studies: a strategy for data (pre‐) processing and validation
  publication-title: Anal Chem
– volume: 61
  start-page: 225
  year: 2020
  end-page: 237
  article-title: Pyruvate metabolism redirection for biological production of commodity chemicals in aerobic fungus
  publication-title: Metab Eng
– volume: 60
  start-page: 2076
  year: 2017
  end-page: 2083
  article-title: Chronic administration of myristic acid improves hyperglycaemia in the Nagoya‐Shibata‐Yasuda mouse model of congenital type 2 diabetes
  publication-title: Diabetologia
– volume: 29
  start-page: 647
  year: 2008
  end-page: 676
  article-title: Glycerolipid metabolism and signaling in health and disease
  publication-title: Endocr Rev
– volume: 20
  start-page: 83
  year: 2018
  article-title: Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis
  publication-title: Arthritis Res Ther
– volume: 114
  start-page: 123
  year: 2021
  end-page: 129
  article-title: Urinary thromboxane B2 and lethal prostate cancer in African American men
  publication-title: J Natl Cancer Inst
– volume: 1864
  start-page: 1031
  year: 2019
  end-page: 1038
  article-title: Myristic acid specifically stabilizes diacylglycerol kinase delta protein in C2C12 skeletal muscle cells
  publication-title: Biochim Biophys Acta Mol Cell Biol Lipids
– volume: 525
  start-page: 406
  year: 2020
  end-page: 411
  article-title: Oleic acid up‐regulates myosin heavy chain (MyHC) 1 expression and increases mitochondrial mass and maximum respiration in C2C12 myoblasts
  publication-title: Biochem Biophys Res Commun
– volume: 111S
  year: 2020
  article-title: The role of omics in the pathophysiology, diagnosis and treatment of non‐alcoholic fatty liver disease
  publication-title: Metabolism
– volume: 94
  start-page: 1726
  year: 2006
  end-page: 1733
  article-title: Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control
  publication-title: Br J Cancer
– volume: 101
  start-page: 55
  year: 2020
  end-page: 64
  article-title: Anti‐inflammatory effect of omega unsaturated fatty acids and dialysable leucocyte extracts on collagen‐induced arthritis in DBA/1 mice
  publication-title: Int J Exp Pathol
– volume: 13
  year: 2021
  article-title: Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
  publication-title: Ther Adv Musculoskelet Dis
– volume: 70
  start-page: 175
  year: 2011
  end-page: 182
  article-title: Chronic low‐grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms
  publication-title: Biol Psychiatry
– volume: 67
  start-page: 1596
  year: 2008
  end-page: 1602
  article-title: Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis
  publication-title: Ann Rheum Dis
– volume: 70
  start-page: 637
  year: 2018
  end-page: 652
  article-title: The tumor‐like phenotype of rheumatoid synovium: Molecular profiling and prospects for precision medicine
  publication-title: Arthritis Rheumatol
– volume: 131
  start-page: 14
  year: 2020
  end-page: 22
  article-title: The lysine degradation pathway: Subcellular compartmentalization and enzyme deficiencies
  publication-title: Mol Genet Metab
– volume: 8
  year: 2020
  article-title: Release of anti‐inflammatory palmitoleic acid and its positional isomers by mouse peritoneal macrophages
  publication-title: Biomedicine
– volume: 10
  year: 2019
  article-title: Disease specific autoantibodies in idiopathic inflammatory myopathies
  publication-title: Front Neurol
– ident: e_1_2_7_29_1
  doi: 10.1038/nrrheum.2014.2
– ident: e_1_2_7_34_1
  doi: 10.3390/biomedicines8110480
– ident: e_1_2_7_12_1
  doi: 10.1002/mas.21455
– ident: e_1_2_7_28_1
  doi: 10.1016/j.bbrc.2020.02.099
– ident: e_1_2_7_14_1
  doi: 10.1042/BJ20130153
– ident: e_1_2_7_36_1
  doi: 10.1016/j.ymben.2020.06.010
– ident: e_1_2_7_26_1
  doi: 10.1159/000364816
– ident: e_1_2_7_23_1
  doi: 10.1016/j.arr.2018.09.004
– ident: e_1_2_7_30_1
  doi: 10.3389/fendo.2019.00870
– ident: e_1_2_7_37_1
  doi: 10.1111/j.1468-3083.2011.04437.x
– ident: e_1_2_7_10_1
  doi: 10.1002/art.40406
– ident: e_1_2_7_17_1
  doi: 10.1016/j.bbalip.2019.04.003
– ident: e_1_2_7_8_1
  doi: 10.1152/physrev.00035.2018
– ident: e_1_2_7_38_1
  doi: 10.1016/j.biopsych.2010.12.006
– ident: e_1_2_7_33_1
  doi: 10.1038/sj.bjc.6603164
– ident: e_1_2_7_44_1
  doi: 10.1016/j.jacc.2016.06.044
– ident: e_1_2_7_32_1
  doi: 10.1007/s11596-014-1271-7
– ident: e_1_2_7_41_1
  doi: 10.1016/j.cmet.2021.03.025
– ident: e_1_2_7_22_1
  doi: 10.1038/nrrheum.2018.48
– ident: e_1_2_7_24_1
  doi: 10.1093/jnci/djab129
– ident: e_1_2_7_15_1
  doi: 10.1016/j.jnutbio.2005.01.010
– ident: e_1_2_7_21_1
  doi: 10.1007/s11010-016-2688-z
– volume: 6
  start-page: 515
  year: 2021
  ident: e_1_2_7_11_1
  article-title: NMR‐based serum and muscle metabolomics for diagnosis and activity assessment in idiopathic inflammatory myopathies
  publication-title: Anal Sci Adv
– ident: e_1_2_7_20_1
  doi: 10.1016/j.fct.2020.111594
– ident: e_1_2_7_6_1
  doi: 10.1186/s13075-018-1579-y
– ident: e_1_2_7_7_1
  doi: 10.1093/rheumatology/keaa473
– ident: e_1_2_7_9_1
  doi: 10.1002/art.41733
– ident: e_1_2_7_27_1
  doi: 10.1111/iep.12348
– ident: e_1_2_7_5_1
  doi: 10.1016/j.semarthrit.2020.05.008
– ident: e_1_2_7_43_1
  doi: 10.1021/ac051495j
– ident: e_1_2_7_35_1
  doi: 10.1002/acr.21879
– ident: e_1_2_7_13_1
  doi: 10.1016/j.metabol.2020.154320
– ident: e_1_2_7_2_1
  doi: 10.1016/S1474-4422(18)30254-0
– ident: e_1_2_7_3_1
  doi: 10.1177/1759720X211060907
– ident: e_1_2_7_25_1
  doi: 10.1136/ard.2007.079525
– ident: e_1_2_7_40_1
  doi: 10.1038/s41467‐019‐11129‐5
– ident: e_1_2_7_42_1
  doi: 10.1210/er.2008-0007
– ident: e_1_2_7_19_1
  doi: 10.1016/0009-8981(83)90186-9
– ident: e_1_2_7_39_1
  doi: 10.1016/j.ymgme.2020.07.010
– ident: e_1_2_7_16_1
  doi: 10.1007/s00125-017-4366-4
– ident: e_1_2_7_18_1
  doi: 10.1093/rheumatology/keg084
– ident: e_1_2_7_31_1
  doi: 10.5606/ArchRheumatol.2016.5696
– ident: e_1_2_7_4_1
  doi: 10.3389/fneur.2019.00438
SSID ssj0000461650
Score 2.3726895
Snippet Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes...
Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based on...
ObjectivesIdiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different subtypes based...
Abstract Objectives Idiopathic inflammatory myopathies (IIM) are a class of autoimmune diseases with high heterogeneity that can be divided into different...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2456
SubjectTerms Algorithms
Autoantibodies
Autoimmune diseases
Bayes Theorem
Biomarkers
Carnitine
Chromatography
Creatine
Discriminant analysis
Disease
Fatty Acids
Humans
Idiopathic inflammatory myopathies
Machine learning
Machine learning algorithm
Metabolism
Metabolites
Metabolomics
Myositis - diagnosis
Original
Plasma
Software
Support vector machines
Urine
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFLbQDsAF8ZvCQEbsAlI0J3Hs-AgT05hULgxpN-v5lyhq0mpphMZfz7OTRq2YxoVb67xWyXuf7c-x3_cIOeLM1w5JW1b73GfclmUG0pmsxJVYFXDKdjzmDs-_irPv_Pyyutwp9RXPhA3ywIPjjqHCZZQHYDa3nAMOngVwK1XgxhkBSWyb1WpnMZXGYC5ykcqzFjFXukIWNGmTFsc_bdfEMsgxh2lnNkqi_Tcxzb8PTN7r2zVc_4Llcp_Uplnp9CF5MNJJ-nF4jEfkjm8fk7vzccP8Cfn9ZSsH4SiM-iN0FegaSXMD2ORofN3uaVRyQiTSPgm60sZvEB3LmLJMx7LeHV20dOEWq1TE2OK3gGhq0i49ba6HZrTqehPf63ZPycXp54uTs2wst5BZZE1VJoHjEwbppWOFg-BrkMx4ZqVVOYjC5zbyndqWee68rAXkHowVHoIyRVk-IwftqvUvCLVWeYlExJYmcMWFcfirGlxuMX4iqBl5v_W6tqMUeayIsdSDiHKhY4R0itCMvJts14MAx41Wn2LwJosomp0aEEp6hJL-F5Rm5HAbej325E7HfWqJq17GZ-TtdBn7YNxYgdaverQRqpAVcke0eT4gZbqTsqoFUwz_XO5haO9W96-0ix9J51tVOBhz9NbRhLZbXfAhAfEWE31-8m2ePr38H_56Re4XMRkkHW08JAebq96_Roq2MW9Sb_wDcZA9DA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZGJwEviDuFgYzYC0jRcnHs5AEhNm0ak1ohGNLeohPbGUVNUpZGaPx6znEuUDH1rXVOK8c-tj_7-HwfY_vCt4lB0OYlNrCe0FHkgTK5F-FOLC5wyTaCcodnc3n6TZxdxBc7bD7kwtC1ymFOdBO1qTWdkR9QvFDh7sMXH1Y_PVKNoujqIKEBvbSCee8oxm6x3ZCYsSZs9_B4_vnLeOpC9OLSybaGlEMdIzoaOUvDgx-6KUkemXKb_lmlHJn_TQj0_4uUd9pqBde_YLncBLtutTq5z-71MJN_7PziAdux1UN2e9YH0h-x358GmgjDoecl4XXBVwimS8Aiw-kY3nJieEIP5a0jeuWlXaPXLCmVmfdy3w1fVHxhFrUTN9b4rUAvK130npfXXTFaNW1O573NY3Z-cnx-dOr1MgyeRjQVewoEvmGhrDJ-aKCwCSg_t75WOg1AhjbQhIMSHQWBsSqREFjItbRQpHkYRU_YpKor-4xxrVOrEKDoKC9EKmRu8FcJmEADbruKdMreDq2e6Z6inJQylllHrhxm1EOZ66EpezParjpijhutDqnzRgsi03YF9dVl1o_NDGLcqVsAXwdaCKyKH4LQKi1EbnIJcsr2hq7P-hHeZH_9ccpej49xbFLABSpbt2gj01DFiCnR5mnnKWNNojiRfurjn6sNH9qo6uaTavHd8X-nMU7SAltrf_S2rU3wzjniFpPs7OjrzH16vv1VX7C7IaV_uMuMe2yyvmrtSwRl6_xVP9L-APaOOkE
  priority: 102
  providerName: ProQuest
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELZgKwEv3MdCQUb0BaSUHI4dP5aKqlTaColWKk_R-Ahsu0lWzUao_fWMnWzUQFUh8ZZ1JpHj_cb-fMw3hGyx0GYGSVuQ2cgGTCdJAMKoIMGZWFrgkG2Yix2eHfL9Y3Zwkp5cieLv9CGGBTfnGb6_dg6-NEXXz_e7-_HHU92ULp8xS2-TDZ4iG5-QjePDrzvfXU45FyWdSp80z1_j2C4HhdKrD4_GJC_dfx3f_PvY5N22WsLFL1gsxtTWj017Dwisv6o7knK23a7Utr78Q_Dxfz77IbnfE1e60yHtEbllq8fkzqzfmn9CLr-shScMhV7phNYFXSI9LwGLDHUL-5Y6zSjEPG29dCwt7QpxuHDB0bRPIN7QeUXnZl77dMkafxWI29KfB6DlRVeMVk2r3Apy85Qc7X0-2t0P-sQOgUZ-lgYCGLZiIawwYWygsBmIUNlQCy0j4LGNtGNWmU6iyFiRcYgsKM0tFFLFSfKMTKq6si8I1VpagZRHJ6pgknFl8KkMTKQBJ3KFnJL36382173oucu9scg7ueY4d22Z-7ackneD7bKT-rjW6pMDyGDh5Ll9QX3-I--9PYcU5_4WINSRZgyrEsbAtJAFU0Zx4FOyuYZX3vcZTe52xAXOr0M2JW-H2-jtbgsHKlu3aMNlLFJkqWjzvEPjUJMkzXgoQ3y5GOF0VNXxnWr-0yuKyxS7fYattTUg-sYm-OAReoNJfrD7beavXv7bO1-Re7ELLPHHJDfJZHXe2tdI91bqTe_RvwGQXVj6
  priority: 102
  providerName: Unpaywall
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fa9UwFA5zgvoi_vbqlIh7UShr0zRpwRcdjjm4Ijhhb-XkR-eV2_ay3iLzr_ectLfj4hj41qanJU2-03xJer7D2L6Mfe6QtEW5T3wkbZpGoJ2JUpyJZRUO2U5S7PD8qzr-IU_OsrMd9mETCzPoQ0wLbuQZ4XtNDg6mO7gSDf1lu5pyGcvsFrudIJEhfAv5bVphISlxFVK0CoqXzpAJTfqk4uDq9q0RKQj3X8c2__1p8m7frODyNyyX28Q2jExHD9j9kVLyjwMGHrId3zxid-bjpvlj9ufLRhLCcRg1SHhb8RUS5xqwyHFacvec1JwQjbwPoq689mtEyJLClvmY2rvji4Yv3KINiYwtnlWIqDrs1PP6cihGq643tLbbPWGnR59PD4-jMeVCZJE5ZZEGiW9Yaa9dLBxUPgcdGx9bbYsElPCJJc6T2zRJnNe5gsSDscpDVRiRpk_ZbtM2_jnj1hZeIxmxqalkIZVxeFcOLrGAU6yqmLF3m1Yv7ShHTlkxluUgpCxK6qEy9NCMvZ1sV4MIx7VWn6jzJgsSzg4F7cV5OfphCRnOyj1AbBMrJVYlFiCtLippnFGgZmxv0_Xl6M1dSXvVGme-sZyxN9Nl9EPaXIHGtz3aqELoDPkj2jwbkDLVJM1yFRcxPlxvYWirqttXmsXPoPVdZPhBltha-xPabmyC9wGIN5iUJ4ff5-Hoxf8Yv2T3BAV-hN8Y99ju-qL3r5COrc3r4HV_AeJfNPc
  priority: 102
  providerName: Wiley-Blackwell
Title Integrated analysis of plasma and urine reveals unique metabolomic profiles in idiopathic inflammatory myopathies subtypes
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.13045
https://www.ncbi.nlm.nih.gov/pubmed/35860906
https://www.proquest.com/docview/2720740704
https://www.proquest.com/docview/2692755604
https://pubmed.ncbi.nlm.nih.gov/PMC9530549
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcsm.13045
https://doaj.org/article/a5713eaa0c1c44a9902a4c79f4bdb6a6
UnpaywallVersion publishedVersion
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: KQ8
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: GX1
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: 7X7
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: BENPR
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: M48
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Open Access Hybrid - NESLI2 2011-2012
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: 40G
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://link.springer.com/
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: U2A
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
– providerCode: PRVWIB
  databaseName: KBPluse Wiley Online Library: Open Access
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: AVUZU
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Open Access
  customDbUrl:
  eissn: 2190-6009
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000461650
  issn: 2190-5991
  databaseCode: 24P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBf9gK0vY9_L1gWNlcEG3vwhS_bDGG1p6QoJYWsgezKyJG8psZ3GMVv21-8ky2ZmoewlJPLFyKeT73c66XcIHRFXRRJAmxMpTzlEBIHDmUydACKxMAOXLYk-Ozwa04spuZyFsx3UbmK3Cqy2hna6ntR0tXj_62bzCSb8R0sg-uFaVLmuakzCN8sbRxeU0olXW11jF-2D04p1VYeRRf7mJU2oR039Vl8fpga3H3fkpX_fseeuDKv_Nij6747Ku3Wx5JuffLHoo17jts7vo3sWb-LjxkAeoB1VPER3Rjaj_gj9_tzyRUjMLUEJLjO8BFSdc2iSWK_HK6ypnkBluDaMrzhXazCfhT7TjG3d7wrPCzyX89JUORbwKwNzy00aH-ebphmkqjrVC7_VY3R1fnZ1euHYegyOAFgVOowTeMKMKSZdX_JMRZy5qXIFE7HHqa88oQFRJALPk4pFlHuKp4IqnsWpHwRP0F5RFuoZwkLEigFSEUGakZjQVMK_Ii49wSH-yuIBettqPRGWq1yXzFgkDcuyn-gRSswIDdDrTnbZMHRslTrRg9dJaFZt01Cuvid2kiY8hJBdce4KTxACXXF9TgSLM5LKlHI6QIft0CetpSY6kc0gLHbJAL3qLsMk1ZkXXqiyBhka-ywEcAkyTxtL6XoShBEF-4Sbs54N9brav1LMfxgi8DiEtzUBbR111narCt4ZQ7xFJLk8_Toy357_x7O8QAe-PgxitjYeor31qlYvAaKt0yHa9ckEPtmMDdH-ydl48mVoljuGZhpC23Q8Of72B-6vRX0
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTWK8IL7pGGDEeAApWuI4cfIwITY2tdtaISjS3izHdqBTm5Sl1VT-N_437twkUDH1bW-tc60c3_m-7PsdIXvct4kBp81LbGA9rsPQU8JkXgiRWJSDyTYca4f7g7j7jZ9eRBcb5HdTC4PXKhud6BS1KTXmyPfxvFBA9OHzD9OfHnaNwtPVpoWGqlsrmAMHMVYXdpzZxTWEcNVB7xPw-y1jJ8fDo65XdxnwNDgLkScUt0bnwgrjM6NymyjhZ9bXQqeBipkNNJr5RIdBYKxIYhVYlenYqjzNGOZDwQJs8ZCnEPttHR4PPn9pkzyIZh67LrEMS7YjcMZaiFS2f6mrCXZjxlKqf4yi6x1wk8P7_73N7XkxVYtrNR6v-tbOOJ7cJ_dqr5Z-XIrhA7Jhi4fkTr8-t39EfvUaVApDVQ2DQsucTsF3nygYMhSz_pYioBRsCDp3uLJ0YmcgpGOsnKZ1d_GKjgo6MqPS9VLW8C0HoZ64ywJ0slgOA1U1zzC9XD0mw9vgxxOyWZSFfUao1qkV4A_pMMt5yuPMwK8SZQKtIMrL0w5516y61DUiOjbmGMslljOTyCHpONQhb1ra6RIH5EaqQ2ReS4HY3W6gvPoua1UgVSSC0Crl60BzDlPxmeJapDnPTBaruEN2G9bLWqFU8q_4d8jr9jGoAjzfUYUt50ATp0xE4MICzdOlpLQzCaMk9lMf_lysyNDKVFefFKMfDm48jcAmcFitvVba1i7BeyeIa0jk6dHXvvu0s_5VX5Ht7rB_Ls97g7Pn5C7DyhN3j3KXbM6u5vYF-IOz7GW96yiRt7zP_wBk5niV
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIQ1eEN_rGGDEeAApauI4cfKAEGxU60YnJIbUN8uxHShqk25pNZX_jP-OO-cDKqa-7a11rpXjO9-dz3e_I-SA-zYx4LR5iQ2sx3UYekqYzAvhJBblYLINx9rh0Vl8_I2fjKPxFvnd1sJgWmWrE52iNqXGGHkf7wsFnD583s-btIgvR4P38wsPO0jhTWvbTqMWkVO7uoLjW_VueAS8fs3Y4NP54bHXdBjwNDgKkScUt0bnwgrjM6NymyjhZ9bXQqeBipkNNJr4RIdBYKxIYhVYlenYqjzNGMZCQfvfEmGYYjahGIsuvIM45rHrD8uwWDsCN6wDR2X9n7qaYR9mLKL6xxy6rgHXubr_Z2zeXhZztbpS0-m6V-3M4uAeudv4s_RDLYD3yZYtHpCdUXNj_5D8GrZ4FIaqBgCFljmdg9c-UzBkKMb7LUUoKdgKdOkQZenMLkA8p1gzTZu-4hWdFHRiJqXroqzhWw7iPHNpAnS2qoeBqlpmGFiuHpHzm-DGY7JdlIXdJVTr1ArwhHSY5TzlcWbgV4kygVZwvsvTHnnTrrrUDRY6tuSYyhrFmUnkkHQc6pFXHe28RgC5luojMq-jQNRuN1BefpeNEpAqEkFolfJ1oDmHqfhMcS3SnGcmi1XcI_st62WjSir5V_B75GX3GJQA3uyowpZLoIlTJiJwXoHmSS0p3UzCKIn91Ic_F2sytDbV9SfF5IcDGk8jsAYcVuugk7aNS_DWCeIGEnly-HXkPu1tftUXZAd2t_w8PDt9Su4wLDlxCZT7ZHtxubTPwBFcZM_dlqNE3vAW_wMwaHYv
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELZgKwEv3MdCQUb0BaSUHI4dP5aKqlTaColWKk_R-Ahsu0lWzUao_fWMnWzUQFUh8ZZ1JpHj_cb-fMw3hGyx0GYGSVuQ2cgGTCdJAMKoIMGZWFrgkG2Yix2eHfL9Y3Zwkp5cieLv9CGGBTfnGb6_dg6-NEXXz_e7-_HHU92ULp8xS2-TDZ4iG5-QjePDrzvfXU45FyWdSp80z1_j2C4HhdKrD4_GJC_dfx3f_PvY5N22WsLFL1gsxtTWj017Dwisv6o7knK23a7Utr78Q_Dxfz77IbnfE1e60yHtEbllq8fkzqzfmn9CLr-shScMhV7phNYFXSI9LwGLDHUL-5Y6zSjEPG29dCwt7QpxuHDB0bRPIN7QeUXnZl77dMkafxWI29KfB6DlRVeMVk2r3Apy85Qc7X0-2t0P-sQOgUZ-lgYCGLZiIawwYWygsBmIUNlQCy0j4LGNtGNWmU6iyFiRcYgsKM0tFFLFSfKMTKq6si8I1VpagZRHJ6pgknFl8KkMTKQBJ3KFnJL36382173oucu9scg7ueY4d22Z-7ackneD7bKT-rjW6pMDyGDh5Ll9QX3-I--9PYcU5_4WINSRZgyrEsbAtJAFU0Zx4FOyuYZX3vcZTe52xAXOr0M2JW-H2-jtbgsHKlu3aMNlLFJkqWjzvEPjUJMkzXgoQ3y5GOF0VNXxnWr-0yuKyxS7fYattTUg-sYm-OAReoNJfrD7beavXv7bO1-Re7ELLPHHJDfJZHXe2tdI91bqTe_RvwGQXVj6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Integrated+analysis+of+plasma+and+urine+reveals+unique+metabolomic+profiles+in+idiopathic+inflammatory+myopathies+subtypes&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Liu%2C+Di&rft.au=Zhao%2C+Lijuan&rft.au=Jiang%2C+Yu&rft.au=Li%2C+Liya&rft.date=2022-10-01&rft.issn=2190-6009&rft.eissn=2190-6009&rft.volume=13&rft.issue=5&rft.spage=2456&rft_id=info:doi/10.1002%2Fjcsm.13045&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon